Log in

NASDAQ:MCRB - Seres Therapeutics Stock Price, Forecast & News

$3.13
-0.39 (-11.08 %)
(As of 01/27/2020 02:08 AM ET)
Today's Range
$3.08
Now: $3.13
$3.55
50-Day Range
$2.87
MA: $3.68
$4.41
52-Week Range
$2.02
Now: $3.13
$8.39
Volume278,328 shs
Average Volume223,923 shs
Market Capitalization$219.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.27 million
Book Value($1.18) per share

Profitability

Net Income$-98,940,000.00
Net Margins-194.04%

Miscellaneous

Employees145
Market Cap$219.13 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.


Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.23) EPS for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.03. The biotechnology company had revenue of $7.03 million for the quarter, compared to the consensus estimate of $6.69 million. View Seres Therapeutics' Earnings History.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Seres Therapeutics.

What price target have analysts set for MCRB?

6 brokerages have issued 1 year price objectives for Seres Therapeutics' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Seres Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 187.5% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.

What is the consensus analysts' recommendation for Seres Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.

What are Wall Street analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:
  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/29/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects." (5/7/2019)
  • 3. HC Wainwright analysts commented, "We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success." (5/3/2019)

Has Seres Therapeutics been receiving favorable news coverage?

Media stories about MCRB stock have trended extremely negative on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Seres Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Seres Therapeutics.

Are investors shorting Seres Therapeutics?

Seres Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,970,000 shares, an increase of 6.7% from the December 15th total of 3,720,000 shares. Based on an average daily trading volume, of 203,200 shares, the days-to-cover ratio is currently 19.5 days. Currently, 9.7% of the company's shares are short sold. View Seres Therapeutics' Current Options Chain.

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Verastem (VSTM), Anavex Life Sciences (AVXL) and Baidu (BIDU).

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:
  • Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)
  • Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)
  • Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)
  • Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)
  • Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $3.13.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $219.13 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.View Additional Information About Seres Therapeutics.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is http://www.serestherapeutics.com/.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]


MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  736
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel